NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207

Group 1 - Alto Neuroscience has successfully raised $120 million in private placement financing to support the development of its psychiatric medication matching platform, ALTO-207 [5] - The funding aims to enhance the company's mission of aligning patients with appropriate psychiatric treatments [5] - The announcement comes amid broader market movements, including a rise in stocks and a retreat in oil prices following geopolitical developments [5] Group 2 - KPMG is set to present findings from a new survey regarding the use of AI in the workplace during an upcoming NYSE Live event [5] - The RSAC Conference, which focuses on cybersecurity innovation and AI-driven defense, is commencing in San Francisco [5]